ClinicalTrials.gg
CompletedNCT03427918Updated Jan 11, 2023

The Effectiveness of the Mindfulness-based Cognitive Therapy (MBCT) on Sexual Functioning in Epileptic Women

An interventional study of Mindfulness-Based Sex Therapy in Epilepsy and Sexual Dysfunction, sponsored by Qazvin University Of Medical Sciences. Completed at 15 sites in Iran, Islamic Republic of. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by Qazvin University Of Medical Sciences · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Study summary

Female sexual dysfunction (FSD) includes impairments in sexual desire, arousal, orgasm, and genital pain resulting in significant subjective distress. This study is aimed to assess a mindfulness-based intervention for improving sexual functioning among women with epilepsy

02

Conditions studied

  • Epilepsy
  • Sexual Dysfunction
03

In context

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 422 are open to participants now.

This study's enrollment of 660 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

Qazvin University Of Medical Sciences is the lead sponsor of 34 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65 years or older
  • Female sexual dysfunctions are categorized by the as sexual interest/arousal disorder, genitopelvic pain/penetration disorder, and female orgasmic disorder. The diagnoses require symptoms to be present for six months or more,
  • Currently in a relationship that has lasted longer than 1 year
  • Both members of the couple are able to speak and read Persian
  • Both members of the couple provide signed and dated form

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment or mental illness that would impair ability to provide consent or participate in the program
  • Major psychiatric disorder (e.g., psychosis, personality disorder)
  • Current suicidal ideation or suicide attempt within past 3 months
  • Past participation in an MBCT program
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
660 participants (actual)

Study arms

  • Experimental
    patient-partner

    patients and their partners will receive a weekly Mindfulness-Based Sex Therapy program. The treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.

    Behavioral: Mindfulness-Based Sex Therapy

  • Experimental
    patient-partner and health care providers

    patients and their partners as well as health care providers will receive a weekly Mindfulness-Based Sex Therapy program. Th treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.

    Behavioral: Mindfulness-Based Sex Therapy

  • No intervention
    Control group

    The control group will receive a routine counseling

Interventions

  • BehavioralMindfulness-Based Sex Therapy

    Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.

06

What researchers measure

Primary outcomes

  1. Sexual functioning

    Sexual functioning is assessed using self-reported measure , female Sexual Function Index (FSFI)

    Time frame: changes from baseline, 1 Months and 6 months

  2. Intimacy

    Personal Assessment of Intimacy in Relationships (PAIR) will use to assess relationship satisfaction. The PAIR is a self-reported measure with 36 items which cover five subscales

    Time frame: changes from baseline, 1 Months and 6 months

  3. sexuality-related distress

    The Female Sexual Distress Scale revised version (FSDS-R) is extensively validated and among the most widely used tools to measure sexually related personal distress.

    Time frame: changes from baseline, 1 Months and 6 months

Secondary outcomes

  1. Mindfulness for sexual functioning

    Sexual Five-Facet Mindfulness Questionnaire (FFMQ-S) is used to assess mindfulness in the context of sexual encounters.

    Time frame: changes from baseline, 1 Months and 6 months

  2. Marital satisfaction

    The Maudsley Marital Questionnaire (MMQ) is a 20-item instrument measuring marital satisfaction.

    Time frame: changes from baseline, 1 Months and 6 months

  3. Psychological distress

    Hospital Anxiety and Depression Scale (HADS) is a brief self-administrated tool to assess psychological distress in patients as well as general populations

    Time frame: changes from baseline, 1 Months and 6 months

  4. Erectile Function

    International Index of Erectile Function Questionnaire (IIEF) is a self-reported and multidimensional measure of male's sexual function

    Time frame: changes from baseline, 1 Months and 6 months

  5. quality of life

    QOLIE-31-P will be used to assess patient's quality of life

    Time frame: changes of QOLIE-31-P from baseline, 1 Months and 6 months

07

Study locations

15 sites
  • Abbasi
    Karaj, Iran, Islamic Republic of
  • Brain and Neuropsychological Clinic
    Karaj, Iran, Islamic Republic of
  • Shahid Madani
    Karaj, Iran, Islamic Republic of
  • Shahid Rejaei
    Karaj, Iran, Islamic Republic of
  • Mehregan
    Qazvin, 3419759811, Iran, Islamic Republic of
  • Razi Hospital
    Qazvin, Iran, Islamic Republic of
  • Attar clinic
    Tehran, Iran, Islamic Republic of
  • Baharlu Hospital
    Tehran, Iran, Islamic Republic of
  • Lolagar Hospital
    Tehran, Iran, Islamic Republic of
  • Raha
    Tehran, Iran, Islamic Republic of
  • Rasoul Akram Hospital
    Tehran, Iran, Islamic Republic of
  • Rezaei Clinic
    Tehran, Iran, Islamic Republic of
  • Sadaf
    Tehran, Iran, Islamic Republic of
  • Sina
    Tehran, Iran, Islamic Republic of
  • Ziaeian
    Tehran, Iran, Islamic Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Mar 2019, 13 months.

Of 337 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's 13 months is below that.

Counting every sponsor, half of 358 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2017
First posted
Feb 9, 2018
StartActual
Feb 1, 2018
Primary completionActual
Mar 30, 2019
CompletionActual
Mar 30, 2019
Last update
Jan 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03427918
Lead sponsor
Qazvin University Of Medical Sciences
Responsible party
Amir H Pakpour (Director of Social Determinants of Health Research Center (SDH), Qazvin University Of Medical Sciences) — Principal investigator
First posted
Feb 9, 2018
Start date
Feb 1, 2018
Primary completion
Mar 30, 2019
Completion
Mar 30, 2019
Last update
Jan 11, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion